Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371071 | 0.98 | CYP2D6 (0.42) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL15372476 | 0.94 | GNAI3 (0.36) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL4368185 | 0.94 | GNAI3 (0.36) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL10867271 | 0.88 | CYP2D6 (0.44) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL10927718 | 0.87 | GNAI3 (0.50) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL4368182 | 0.84 | CYP2D6 (0.41) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL88162 | 0.83 | CYP2D6 (0.47) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL88163 | 0.83 | CYP2D6 (0.47) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL4370689 | 0.82 | CYP2D6 (0.44) | CYP2D6MEN1ALDH1A1LMNATP53 | |
| SCHEMBL29876705 | 0.81 | FDPS (0.40) | CYP2D6MEN1ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393918-A1 | SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | CYP2D6 334/4885MEN1 3708/4885ALDH1A1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.